Compare DFLI & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | NUWE |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.2M |
| IPO Year | 2021 | 2012 |
| Metric | DFLI | NUWE |
|---|---|---|
| Price | $1.69 | $3.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | 57.4K | ★ 1.4M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,630,000.00 | $8,270,000.00 |
| Revenue This Year | N/A | $19.32 |
| Revenue Next Year | $36.41 | $12.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.77 | N/A |
| 52 Week Low | $0.41 | $0.28 |
| 52 Week High | $5.15 | $222.30 |
| Indicator | DFLI | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 40.20 |
| Support Level | $1.68 | $0.28 |
| Resistance Level | $2.24 | $5.74 |
| Average True Range (ATR) | 0.20 | 0.51 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 28.87 | 0.86 |
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.